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Aim: To determine the effects of a Mediterranean-style low-glycemic load diet alone or 
in combination with a medical food (MF) on insulin resistance and inflammation in 
women with metabolic syndrome (MetS). 
Study design:  Two groups, Parallel study with control. 
Place and Duration of Study: Department of Nutritional Sciences, University of 
Connecticut, Storrs, CT; Department of Emergency Medicine, University of Florida, 
Jacksonville, FL; Department of Medicine, University of California, Irvine, CA. The study 
was carried out from September of 2009 to May 2010. 
Methodology: Eighty three women (20-75 y) with MetS. Participants were randomly 
allocated to consume diet alone (control group) or the diet plus the MF (MF group) for 
12 wk. Body composition was measured at baseline, week 8 and week 12 by use of 











used for 37 of the subjects. Insulin resistance, plasma insulin, leptin, adiponectin and 
the inflammatory cytokines, tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), adhesion 
molecules, sICAM-1 and sVCAM-1, were measured at the same time points. 
Results: Independent of group allocation, women had decreases in body mass index (p 
< 0.0001) and body and trunk fat (p < 0.0001). Plasma insulin, insulin resistance, and 
leptin were also significantly decreased over time (p < 0.0001), while plasma 
adiponectin levels did not change. Regarding inflammatory markers, significant 
reductions were found in TNF-α (p < 0.0001) and sICAM-1 levels (p < 0.001), but not in 
IL-6 or sVCAM-1.  At 12 wk, sICAM was reduced only in the MF group (p<0.05 vs 
control). 
Conclusion: A Mediterranean-style diet, in combination with a MF, are a viable option 
to decrease factors associated with increased risk for type 2 diabetes and coronary 
heart disease. 
 
Keywords: Metabolic syndrome; mediterranean diet; glycemic load; insulin; inflammation; 
body composition; 
 




BMI: body mass index; BP: blood pressure; CVD: cardiovascular disease; DEXA: dual-
energy X-ray absorptiometry; HDL-C: HDL cholesterol; ICAM: Intracellular adhesion 
molecule; IL-6: interleukin-6; LDL-C: LDL cholesterol; MetS: Metabolic syndrome; NHANES: 
National Health and Nutrition Examination Survey; T2D: type 2 diabetes; TNF-α: tumor 





1. INTRODUCTION  
 
Insulin resistance, the diminished capacity of a cell to respond to insulin action, has been 
established as a primary underlying cause of metabolic syndrome (MetS) development 
(Lann, Gallagher et al. 2008; Gallagher, Leroith et al., 2010; Maheshwari and Thuluvath, 
2011). An individual is classified as having MetS if 3 of the following criterion are met: 
hyperglycemia, high waist circumference (WC), elevated blood pressure (BP), elevated 
triglycerides (TG), and low high-density lipoprotein cholesterol (HDL-C) (Alberti, Eckel et al. 
2009). According to the National Health and Nutrition Examination Survey (NHANES) 2003-
2006, approximately one-third of the US adult population is affected by MetS, and this 
significantly increases the risk for developing cardiovascular disease (CVD) and type 2 
diabetes (T2D) (Ervin 2009).  
 
While insulin resistance is often considered the causal feature for development of MetS, 
abdominal obesity is also a major contributor and the two components are clearly related 
(Després, 2006; Després, Lemieux et al., 2008; Westphal, 2008; Reddy, Singh et al., 2010). 
Adipose tissue is considered an active endocrine organ (Wozniak, Gee et al., 2009; Han and 
Lean, 2011), responsible for secreting biologically active molecules, collectively termed 










adipokines such as adiponectin, leptin, interleukin 6 (IL-6) and tumor necrosis factor alpha 
(TNF-α) can be negatively altered (Lago, Dieguez et al., 2007; Lago, Gómez et al., 2009), 
which can in turn influence energy regulation and inflammation (Han and Lean, 2011). 
Adiponectin, an insulin sensitizer with anti-inflammatory properties, tends to be decreased in 
obesity and MetS (Ryo, Nakamura et al. 2004; Huang 2009). Leptin is important for 
regulation of appetite and energy balance. In obese individuals, despite elevated leptin 
concentrations, sensitivity to this molecule has been shown to decrease (Gnacińska, 
Małgorzewicz et al., 2009). Proinflammatory adipokines, IL-6 and TNF-α, also tend to be 
upregulated in obesity, and these molecules have a role in insulin resistance and endothelial 
dysfunction (Ryo, Nakamura et al. 2004; Maury and Brichard 2010; Van Linthout, Foryst-
Ludwig et al. 2010). These inflammatory mediators alter insulin sensitivity via action on 
nuclear factor kappa B (NFкB) and jun N-terminal kinase (JNK) pathways, and they facilitate 
expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1), which both play a role in atherogenesis (Lyon, Law et al., 2003; 
Shoelson, Herrero et al., 2007). Obesity has also been associated with macrophage 
accumulation in adipose tissue, and this could further contribute to the production of 
proinflammatory cytokines (Weisberg, McCann et al., 2003).  
 
The central focus to treat inflammation, excess abdominal fat stores, and insulin resistance 
that compose MetS, remains lifestyle modification. Various researchers have highlighted the 
potential efficacy of adherence to a Mediterranean-style diet for treatment of MetS 
characteristics (Babio, Bulló et al., 2009; Sofi, 2009; Kastorini, Milionis et al., 2011). 
Epidemiological data suggest that prevalence of MetS tends to be associated with dietary 
patterns that contain excessive amounts of high glycemic index foods (Baxter, Coyne et al. 
2006). Therefore, our aim was to examine the impact of a low-glycemic-load Mediterranean-
style diet on specific MetS variables, namely inflammation, insulin resistance, and obesity. 
Additionally, our objective was to assess whether a medical food (MF), containing rho iso-
alpha acids from hops (Humulus lupulus L.) and proanthocyanidins from acacia (Acacia 
nilotica), which may modulate insulin-signaling and inflammatory pathways (Lerman, Minich 
et al., 2008), provided further benefits. We hypothesized that following this dietary 
intervention would result in similar weight loss for all participants, but the group consuming 
the MF would have greater improvements in insulin sensitivity and present a better 
inflammatory profile.    
  
2. METHODS  
 
2.1 Materials  
 




) was provided by Metagenics, Inc (Gig Harbor, 
WA), in powdered form.  Kits to measure adiponenctin, sICAM, sVCAM, TNF-α and IL-6 
were obtained from Millipore (Billerica, MA). 
 
2.2 Study Population  
 
Women were recruited at three sites (University of Connecticut, Storrs, CT; University of 
Florida, Jacksonville, FL and University of California, Irvine, CA). To be eligible for 
participation, women had to be between the ages of 20 and 75 years with a BMI between 25 
and 45 kg/m
2
. In addition, they had to have LDL-C ≥ 100 mg/dL (2.59 mmol/L), TG ≥ 150 
mg/dL (1.70 mmol/L), and meet two of the four remaining criteria for MetS according to 










mg/dL (5.55 mmol/L), blood pressure (BP) > 130/85 mm Hg, and WC > 88 cm) (ATP, (2002). 
Main exclusion criteria included heart, liver, or kidney disease and use of hypoglycemic or 
cholesterol-lowering agents. Potential participants provided informed consent during 
screening and before the study began. The women also provided a medical history prior to 
participation. Study protocols and the procedures to obtain consent forms were approved by 
the Institutional Review Board at each respective site.   
 
2.3 Study Design 
 
After entrance criteria were met and consent was obtained, women were randomly allocated 
to the control group or the medical food (MF) group. Both groups were given detailed 
instructions to consume a modified Mediterranean-style, low-glycemic-load diet for the 
duration of the 12-week intervention. Women in the MF group consumed the same diet plus 
a powdered beverage form of a medical food containing soy protein, plant sterols, rho iso-
alpha acids, and Acacia proanthocyanidins, mixed into water, twice each day for 12 weeks. 
Participants came on-site for a baseline visit and returned at weeks 2, 4, 6, 8, 10, and 12 for 
follow-up visits. Compliance with MF intake guideline was assessed by weighing the unused 
powder every 2 weeks. 
 
2.4 Diet and Exercise Description 
 
Participants were invited to an on-site meeting 1 week prior to the start of the study, at which 
time an instructional DVD was viewed and detailed dietary booklets were distributed 
summarizing dietary guidelines, lists of suitable foods, suggested serving sizes, and recipes. 
Subjects were also instructed on how to complete a detailed food record that included 2 
weekdays and one weekend day.  The dietary approach was parallel to that designed by 
Schiltz et al. (Schiltz, Minich et al., 2009). Subjects were advised to follow a Mediterranean-
style diet with emphasis on intake of legumes, fish and lean meats. In addition, specific 
limitations were placed on intake of grains (1 serving per day) and alcohol (an optional 1 
serving per day). Lastly, natural and artificial sweeteners were excluded from the diet. The 
women were not instructed to restrict caloric intake. A 3-day food record was obtained at 
baseline (to assess habitual dietary intake) and every 2 weeks (to assess dietary compliance 
and nutrient intake). The participants met with a Registered Dietitian at each visit for diet 
counseling. Subjects were asked to maintain their normal level of physical activity for the 
entirety of the intervention and 7-day exercise logs were collected to measure compliance 
with this instruction.  
 
2.5 Data Collection  
 
Following a 12-hour overnight fast, 60 mL of blood were collected into EDTA tubes at 
baseline, week 8, and week 12. Plasma was separated by centrifugation at 2000 x g: 20 min 
at 4°C. The plasma was aliquoted to cryotubes and stored at -80 °C and later sent to a 
certified laboratory (Northwest Lipid Research Laboratories, Seattle, WA) for analysis of 
insulin, or used at the University of Connecticut for analysis of adipokines and inflammatory 
markers.  
 
2.6 BMI and Body Composition 
 
At each visit, body weight was measured to the nearest 0.1 kg on a calibrated digital scale, 
and BMI was calculated (kg/m
2










analysis (BIA) was used to assess body composition, utilizing an Impedimed DF 50 (Xitron 
Technologies, San Diego, CA) at all sites. In addition to the BIA, the University of 
Connecticut and the University of California, Irvine, determined whole body and regional 
body composition using fan-beam dual-energy X-ray absorptiometry (DEXA) (Prodigy, 
Lunar Advance Corporation, Madison, WI). Analyses were performed by a technician at the 
respective sites (MF: n = 18, control: n = 17). 
 
2.7 Plasma Insulin and Insulin Resistance 
 
Plasma insulin was measured by a chemiluminescent, immunoassay using the DPC 
Immulite 2000 (Diagnostics Products Corporation, Nutley, NJ) at Northwest Lipid Research 
Laboratories (Seattle, WA). Insulin resistance was calculated using the homeostasis model 
assessment (HOMA) equation ([fasting
 
insulin (µU/ml) x fasting glucose (mmol/l)]/22.5) 
(Muniyappa, Lee et al., 2008). 
 
2.8 Fasting Adiponectin, sVCAM-1, and sICAM-1 
 
Fasting plasma was used to measure concentrations of adiponectin, sVCAM-1, and sICAM-
1 in duplicate using the Milliplex Human CVD Panel 1 (City, State). The samples were 
diluted 1:100 and antibody-immobilized beads specific for each analyte were used for 
simultaneous quantification with xMAP
® 
technology on the Luminex 
® 
IS 200 system (Austin, 
TX).   
 
2.9 Fasting IL-6, TNF-α, and Leptin 
 
Fasting plasma was used to measure concentrations of IL-6, TNF-α, and leptin in duplicate 
using the Milliplex Human Cytokine kit and xMAP
® 
technology on the Luminex 
® 
IS 200 
system (Austin, TX). Specific antibody-immobilized beads were used to simultaneously 
quantify IL-6, TNF-α, and leptin.  
 
2.10 Statistical Analysis 
 
Repeated measures analysis of variance (ANOVA) was used to compare the control and MF 
groups over time. The repeated measure was the individual’s response to the intervention 
over time and the control vs. the MF served as the between subject factors. SPSS 12.0 for 
Windows (SPSS, Inc., Evanston, IL) was used and results were considered significant with a 
p < 0.05.  
 
3. RESULTS  
 
3.1 BMI and Body Composition 
 
Participants in both groups had significant decreases in BMI from baseline to the end of the 
12-week intervention (p < 0.0001, Table 1), but no differences were observed between the 
groups. Examination of BIA measurements revealed that fat mass, in kg and as a 
percentage of total body weight, decreased significantly over time (p < 0.0001 Table 1), 
regardless of group categorization. Likewise, fat free mass in kg decreased in both groups (p 
< 0.0001) while percent of fat free mass increased also for both groups (p < 0.001, Table 1), 










Table 1.  Body mass index (BMI) and body composition as measured by bioelectrical impedance analysis of women 





 BMI Fat Free Mass Fat Mass Fat Free Mass Fat Mass 
 kg/m
2
 kg % 
Medical Food Group 
Baseline 34.9 ± 6.1
a
 50.7 ± 5.7
 a
 41.8 ± 10.5
 a
 55.7 ± 4.3
 a
 44.2 ± 4.3
 a
 
Week 8 33.1 ± 5.5
 b
 49.4 ± 5.4
 b
 38.4 ± 10.6
 b
 57.4 ± 5.9
 b
 42.6 ± 5.9
 b
 
Week 12 32.5 ± 5.8
 b
 48.8 ± 5.2
 b
 37.7 ± 10.4
 b
 57.6 ± 5.7
 b
 42.4 ± 5.7
 b
 
Control  Group 
Baseline 35.0 ± 5.5
 a
 50.7 ± 5.8
 a
 39.4 ± 9.0
 a
 56.0 ± 3.6
 a
 43.9 ± 3.5
 a
 
Week 8 33.1 ± 5.0
 b
 49.7 ± 5.6
 b
 36.1 ± 9.2
 b
 57.8 ± 5.4
 b
 42.2 ± 5.2
 b
 
Week 12 32.7 ± 5.1
 b
 49.5 ± 5.6
 b
 35.3 ± 9.5
 b
 58.4 ± 6.1
 b
 41.7 ± 5.8
 b
 
Time Effect P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.001 
1
Values are expresses as mean ± SD. No diet effects or interactive effects were found for these variables.  




Fig. 1.  Percent Body Fat (A) and Percent Trunk Fat (B) calculated by DEXA at baseline week 8 and week 12 for women 
allocated to Medical
British Journal of Medicine & Medical Research
 











Fig. 2. Body Fat Weight (A) and Trunk Fat Weight (B) calculated by DEXA at baseline week 8 and week 12 for women 
allocated to Medical Food (n = 18) or Control (n = 17). ** p <





















The University of Connecticut and the University of California, Irvine, had access to DEXA, 
which allowed measurements of body fat and trunk fat for a subset of subjects (MF: n = 18, 
control: n = 17). Percent body fat and percent trunk fat decreased in both groups, with no 
differences between groups (p < 0.0001; A and B, respectively, Figure 1).  
 
Similarly, there were no differences between groups in relation to the significant reductions 
observed in kg of body fat and trunk fat (p < 0.0001, A and B, respectively, Figure 2). 
 
3.2 Insulin and Insulin Resistance 
 
Plasma insulin levels decreased in both groups over the course of the 12-week intervention, 
independent of group allocation (p < 0.0001, Table 2). HOMA scores were utilized to assess 
insulin resistance, and both groups displayed reductions in this variable (p < 0.0001, Table 
2), with no between-group differences noted.   
 
Table 2. Changes in insulin and insulin resistance as measured by HOMA ofwomen 
allocated to the Medical Food group (n = 42) or the Control group (n = 41) at baseline, 
week 8 and week 12 of the Intervention
1 
 
 Insulin HOMA* 
 µIU/mL  
Medical Food Group 
Baseline 16.9 ± 9.4
a
 4.25 ± 2.93
 a
 
Week 8 12.3 ± 6.0
 b
 3.01 ± 1.57
 b
 
Week 12 12.6 ± 7.6
 b
 2.99 ± 1.91
 b
 
Control  Group 
Baseline 16.6 ± 9.4
 a
 4.12 ± 2.40
 a
 
Week 8 11.8 ± 5.4
 b
 2.84 ± 1.30
 b
 
Week 12 12.2 ± 5.7
 b
 3.01 ± 1.58
 b
 
Time Effect P < 0.0001 P < 0.0001 
1
Values are expresses as mean ± SD. No diet effects were found for these variables.  
Values with different superscripts are significantly different as compared to baseline. 
 
3.3 Adipokines and Inflammatory Markers 
 
Plasma adiponectin levels did not change significantly in either group over time (Table 3). 
However, changes were observed in plasma levels of leptin (p < 0.0001, Table 3), although 
the changes were not significantly different between groups.  While plasma levels of IL-6 did 
not change significantly in either group (Table 3), there were differences observed over time 
for plasma TNF-α (p < 0.0001, Table 3); however, these were not different between groups 
at the end of the intervention. sICAM-1 decreased in the MF group over time (p < 0.001, 
Table 3), while levels in the control group were not different from baseline in either week 8 or 
12 (Table 3). No significant changes in sVCAM-1 were measured for either group (Table 3).    
 










Table 3. Changes in adiponectin, tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), soluble intercelluar adhesion molecule-
1 (ICAM)-1 and soluble vascular cell adhesion molecule (VCAM)-1 of women allocated to the Medical Food group (n = 42) or 




 Adiponectin Leptin TNF-α IL-6 sICAM-1 sVCAM-1 
 mg/L 
Medical Food Group 
Baseline 15.2 ± 7.9
a
 51.0 ± 30.1
a
 4.6 ± 2.0
 a
 5.1 ± 3.4
 a
 112 ± 55
a
 1.3 ± 3.4
a
 
Week 8 15.7 ± 6.8
 a
 36.5 ± 21.8
 b
 4.3 ± 1.6
b
 4.8 ± 3.2
a
 96 ± 40
b
 1.2 ± 2.9
a
 
Week 12 15.0 ± 10.7
 a
 34.2 ± 23.0
 b
 4.2 ± 1.8
b
 4.7 ± 3.7
a
 96 ± 37
b
 1.2 ± 2.7
a
 
Control  Group 
Baseline 14.2 ± 6.8
 a
 55.5 ± 27.5
 a
 5.4 ± 2.4
 a
 4.3 ± 2.5
a
 105 ± 29
a
 1.2 ± 2.6
a
 
Week 8 13.8 ± 6.0
 a
 41.7 ± 25.8
 b
 5.1 ± 2.1
 ab
 4.0 ± 2.1
a
 99 ± 32
ab
 1.2 ± 3.0
a
 
Week 12 14.8 ± 6.3
 a
 40.4 ± 25.7
 b
 4.3 ± 1.7
 b
 3.9 ± 2.4
a
 103 ± 49
a
 1.2 ± 3.3
a
 
Time Effect NS P < 0.0001 P < 0.0001 NS P < 0.001 NS 
Diet Effect NS NS NS NS P < 0.05 NS 
1










4. DISCUSSION  
 
A consensus has not been reached regarding the best dietary pattern to alleviate 
characteristics of MetS, but the Mediterranean-style pattern has received ample attention 
and is considered an effective option (Djoussé, Padilla et al., 2010). The aim of the current 
study was to evaluate the impact of a Mediterranean-style, low-glycemic-load diet on body 
composition, insulin resistance and inflammation, in a population of women with MetS and 
elevated LDL-C. Another objective was to determine if a phytosterol-rich MF provided any 
additional benefits to these parameters. Following the 12- week intervention, both groups 
showed improvements in body composition, insulin resistance and inflammatory profiles. 
 
Generally, a positive correlation exists between BMI, adiposity and risk for T2D and CVD; 
therefore, BMI is typically considered a suitable tool to define adult obesity (BMI > 30 kg/m
2
) 
and pinpoint individuals that may be at risk of obesity-related morbidity and mortality (2003; 
Westphal 2008). BMI is often used as a surrogate marker of overall obesity, while WC is 
used to assess central obesity. Both of these measurements are easily obtainable indirect 
measurements of obesity (Koopman, Swofford et al., 2009). WC and BMI are strongly 
correlated, and elevated WC alone is a strong predictor of mortality and risk for chronic 
disease development (Phillips and Prins, 2008; Achike, To et al., 2011). Measurements of 
WC are better indicators of body fat distribution, and it is not total body fat, or subcutaneous 
fat, but rather, excess intra-abdominal fat that is highly associated with metabolic 
abnormalities in overweight and obese individuals (Bjorntorp, 1991; Nielsen and Jensen, 
1997; Després, 2006). We previously reported significant reductions in weight and WC for 
the participants of this study ( Jones, Fernandez et al., 2011), and here we show that BMI 
was significantly reduced in both groups post-intervention. While BMI is a standard indirect 
measure of overweight and obesity, it does not distinguish between fat mass and fat free 
mass, nor does it describe body fat distribution (Boardley and Pobocik, 2009). 
 
In order to provide a more comprehensive account of changes in body composition over the 
course of the intervention, BIA and DEXA measurements were utilized. Results from the BIA 
showed that all participants had significant reductions in absolute (kg) and relative (%) 
amounts of fat mass while percent free fat mass increased after the intervention. Results 
from DEXA assessment revealed significant decreases in body fat and trunk fat, on a 
percentage and weight basis. While the decreases in fat mass are desirable, those observed 
in fat free mass (specifically lean mass) are less so, but it is acknowledged that body weight 
decreased and percent lean increased over time. Abdominal obesity has been considered a 
dominant cause of MetS (Després, 2006); therefore, the specific losses in trunk fat may 
decrease cardiometabolic risk (Katsoulis, Blaudeau et al., 2009). 
 
Weight loss, and especially abdominal fat loss, has been associated with improvements in 
insulin resistance (Weiss, 2007; Bellar, Jarosz, et al., 2008; Aasen, Fagertun et al., 2010). In 
a previous study of similar design to the current one, supplementation with a MF and 
identical phytochemical-combination increased insulin sensitivity (Lerman, Minich et al., 
2008), it was the expectation that the same observation would be made following this 
intervention. While we did measure significant reductions in insulin, and improvements in 
HOMA-IR scores, the changes were not statistically different between groups. Insulin 
resistance is associated with CVD (Ferrannini, Balkau et al., 2007), and if ignored, can 
progress to T2D (Phillips and Prins, 2008). In conjunction with improvements in insulin 
resistance, we expected to observe increases in plasma adiponectin, which has insulin-
sensitizing and anti-inflammatory properties (Matsuzawa, 2010). However, we did not obtain 










no changes in adiponectin levels, despite weight loss in women (Shin, Yoen Kim, et al., 
2006; Polak, Kovacova et al., 2008). This suggests that other weight loss-associated factors, 
in organs other than adipose, may account for the improved insulin variables.  
 
Despite the lack of weight-loss induced change on adiponectin, leptin levels did decrease 
significantly in both groups over time. Leptin, an adipokine responsible for increasing energy 
expenditure and suppressing food intake (Matsuzawa, 2005), tends to be elevated in obese 
individuals, indicative of leptin resistance (Gade, Schmit et al., 2010; Münzberg, 2010). 
Therefore, the decreases observed may suggest improved sensitivity to leptin. The 
significant decreases observed in trunk fat may also contribute to the reductions in plasma 
levels of TNF-α. In an obese state, adipocyptes can overproduce cytokines such as TNF-α 
and IL-6 (Jensen, 2006). These molecules in turn recruit monocytes to the adipose tissue 
and facilitate their differentiation to active macrophages, which can produce more pro-
inflammatory molecules, intensifying the systemic metabolic dysfunction associated with 
obesity (Ouchi, Parker et al., 2011; Vykoukal and Davies, 2011). We did not observe 
substantial changes in IL-6, but the reductions in TNF-α are indicative of a less inflammatory 
profile. Another marker of inflammation, and more specifically of endothelial function, sICAM-
1 was also reduced, but only in the MF group. ICAM-1 responds to inflammatory conditions 
and mediates the migration of leukocytes into tissues (Hubbard and Rothlein, 2000). There 
is a tendency for ICAM-1 to be elevated in obesity, and it has been positively correlated with 
central adiposity and insulin resistance (Straczkowski, Lewczuk et al., 2002; Leinonen, Hurt-
Camejo et al., 2003). In agreement with the similar reductions we recorded in abdominal fat 
and insulin resistance for both groups, the decreases in sICAM-1 were expected regardless 
of group distribution. However, we only observed changes in the MF for this variable. VCAM-
1, another marker of endothelial function was not significantly modified in either group 
following the intervention.    
      
We acknowledge the limitation of only utilizing DEXA, the gold-standard to assess body 
composition, for a subset of study participants. It may also have been beneficial to assess 
adiponectin levels using a more sensitive assay, such as an ELISA, but sample availability 




Overall, following the 12-week intervention, BMI decreased significantly in both groups, but 
not enough on average to remove participants from the obese category (BMI > 30 kg/m
2
). 
However, direct analysis of body composition, with BIA and DEXA, revealed significant 
decreases in abdominal fat mass. These data, in combination with the previously reported 
WC information (Jones, Fernandez et al., 2011), substantiate the possible benefits of a 
Mediterranean-style dietary pattern for obesity treatment, and more specifically for visceral 
adipose reduction. Furthermore, insulin resistance and leptin sensitivity were improved in all 
participants. The MF appeared to improve endothelial function, as evidenced by the 
reductions in sICAM-1, which were not observed in the control group. In total, adherence to 
a low-glycemic-load, Mediterranean-style diet appears to positively influence body 
composition and insulin resistance in women with MetS and elevated LDL-C.   
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